Thymosin Alpha-1: The Immune Peptide Approved in 35+ Countries

Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide originally isolated from calf thymus in the 1970s by Allan Goldstein and colleagues (Goldstein et al., 1977). Tα1 has been approved as a pharmaceutical drug (marketed as Zadaxin®) in over 35 countries for the treatment of hepatitis B, hepatitis C, and as an immune adjuvant, according to a 2009 review (Goldstein et al., 2009). It remains one of the most clinically studied peptides in the world.

Mechanism of Action

Tα1 is classified in the literature as an immunomodulator rather than a general immunostimulant, a distinction with mechanistic relevance to autoimmune contexts. Reported mechanisms include:

• T-Cell Maturation: Identified as one of several thymic peptides thought to regulate the differentiation and function of T cells (Goldstein et al., 1977). Thymic involution with age reduces naive T-cell output.
• Dendritic Cell Activation: Induces maturation and IL-12 production in dendritic cells, supporting antifungal immunity in mice (Romani et al., 2004).
• NK Cell Activity: In mouse tumour studies, Tα1 combined with interferon after chemotherapy strongly increased natural killer cell activity, although Tα1 alone had little effect (Garaci et al., 1990).
• Toll-Like Receptor Signalling: Signals through Toll-like receptor pathways in dendritic cells, including TLR9 in plasmacytoid dendritic cells, in mouse and cell studies (Romani et al., 2007).
• Cytokine Modulation: Reported in cell and animal studies both to promote immune activation and to help restrain excessive inflammation, partly through effects on dendritic cells (Romani et al., 2007).

Clinical Evidence

Hepatitis B & C

Tα1 is approved in multiple countries for chronic hepatitis B treatment. A 2011 meta-analysis of seven small trials (535 patients) reported higher rates of HBV DNA clearance and HBeAg loss with Tα1 plus interferon-alpha than with interferon alone (Mao et al., 2011), but a 2026 Cochrane review of 10 trials judged the evidence on clinical outcomes to be of low or very low certainty (Naing et al., 2026). In hepatitis C, a 109-patient randomised trial found higher end-of-treatment biochemical response rates with Tα1 plus interferon than with interferon alone (37% versus 16%), but sustained responses were low in both groups (14% versus 8%) (Sherman et al., 1998).

Cancer Immunotherapy Research

Many clinical trials, most of them small, have evaluated Tα1 as an adjunct to chemotherapy and immunotherapy. Studies in non-small cell lung cancer and melanoma reported improved immune function markers, reduced chemotherapy-related immunosuppression, and in some studies, improved survival outcomes. In a 488-patient melanoma trial, two of the groups given Tα1 alongside chemotherapy had more tumour responses than the control group, with a non-significant trend towards longer survival (Maio et al., 2010). A 2019 meta-analysis of 27 Chinese trials in non-small cell lung cancer (1,925 patients) reported higher response and 1-year survival rates when synthetic thymic peptides, mainly Tα1, were added to chemotherapy, but rated the evidence as moderate to very low quality (Zeng et al., 2019). An earlier Cochrane review found only a non-significant trend towards longer survival with Tα1 (Wolf et al., 2011).

Sepsis

The TESTS trial (2025), a large multicentre Phase III RCT of 1,106 adults with sepsis in China published in the BMJ, found no difference in 28-day mortality between Tα1 and placebo (23.4% versus 24.1%) (Wu et al., 2025). Prespecified subgroup analyses suggested possible differences in effect by age and by diabetes status, which would need confirmation in further trials.

Vaccine Adjuvant Research

Tα1 has been studied as a vaccine adjuvant in older people, whose vaccine response rates are typically lower. In a double-blind, placebo-controlled study in elderly men, Tα1 given alongside influenza vaccination improved antibody responses (Gravenstein et al., 1989).

Trial Duration Data

Administration details fall outside the scope of research-use-only material. Treatment periods in the trials cited here ranged from seven days in sepsis (Wu et al., 2025) to 26 weeks in hepatitis C (Sherman et al., 1998).

In the trials cited here, Tα1 was generally well tolerated: the large sepsis trial found no difference in safety outcomes versus placebo (Wu et al., 2025), adding it to melanoma chemotherapy did not add toxicity (Maio et al., 2010), and the Cochrane review of hepatitis B trials found no increase in serious adverse events (Naing et al., 2026).

Relevance to Ongoing Peptide Research

Tα1 sits in a unique position: it has genuine pharmaceutical approval and decades of clinical trial data, yet remains relatively unknown outside specialist immunology circles. For researchers studying immune ageing (immunosenescence) or immune modulation under physiological stress, Tα1 has a larger clinical evidence base than almost any other peptide in circulation, although recent reviews rate much of that evidence as low certainty.

Research Considerations

• Tα1 is reported to modulate, rather than simply stimulate, the immune system. Baseline immune status is a relevant variable in trial design, typically assessed via full blood count and white cell differential.
• Any immune modulator carries a theoretical risk of flare in autoimmune conditions.
• Material provenance and independent testing are relevant to data quality in laboratory studies.
• This is educational content summarising published research, not medical advice.

References

1. Garaci E, et al. (1990). Combination treatment using thymosin alpha 1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice. Cancer Immunology, Immunotherapy. PubMed 2126987
2. Goldstein AL, et al. (1977). Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proceedings of the National Academy of Sciences. PubMed 265536
3. Goldstein AL, et al. (2009). From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opinion on Biological Therapy. PubMed 19392576
4. Gravenstein S, et al. (1989). Augmentation of influenza antibody response in elderly men by thymosin alpha one. A double-blind placebo-controlled clinical study. Journal of the American Geriatrics Society. PubMed 2642497
5. Maio M, et al. (2010). Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. Journal of Clinical Oncology. PubMed 20194853
6. Mao HY, et al. (2011). Treatment with interferon and thymosin alpha-1 versus interferon monotherapy for HBeAg positive chronic hepatitis B: a meta-analysis (article in Chinese). Chinese Journal of Hepatology. PubMed 21272455
7. Naing C, et al. (2026). Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database of Systematic Reviews. PubMed 42713852
8. Romani L, et al. (2004). Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood. PubMed 14982877
9. Romani L, et al. (2007). Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance. Annals of the New York Academy of Sciences. PubMed 17495242
10. Sherman KE, et al. (1998). Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. Hepatology. PubMed 9537454
11. Wolf E, et al. (2011). Thymic peptides for treatment of cancer patients. Cochrane Database of Systematic Reviews. PubMed 21328265
12. Wu J, et al. (2025). The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. PubMed 39814420
13. Zeng FL, et al. (2019). Clinical efficacy and safety of synthetic thymic peptides with chemotherapy for non-small cell lung cancer in China: A systematic review and meta-analysis of 27 randomized controlled trials following the PRISMA guidelines. International Immunopharmacology. PubMed 31326719